Every year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together thousands of cancer researchers, oncologists, and advocates to discuss the latest cancer research. Some studies presented at ASCO may eventually change how breast cancer is treated. Others help answer important questions patients have been asking for years. Not every study presented at ASCO will immediately change care. But some have the potential to shape conversations between patients and their healthcare teams in meaningful ways.
This year, several breast cancer studies drew significant attention because they focused on issues patients care deeply about, including whether chemotherapy can safely be avoided, how treatment decisions may become more personalized through blood testing, and whether newer therapies can improve outcomes in difficult-to-treat cancers.
Here are six breast cancer studies our patient advocates say we should pay attention to following ASCO 2026.
1. OPTIMA: Can more patients safely avoid chemotherapy?
For many people diagnosed with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer, one of the biggest questions is whether chemotherapy is truly necessary. The OPTIMA trial looked at whether genomic testing can better identify which patients are likely to benefit from chemotherapy and which patients may be able to safely avoid it, even in some higher-risk situations such as node-positive disease. This matters because chemotherapy can come with both short- and long-term side effects, and many patients want to avoid overtreatment when possible.
The OPTIMA trial adds to growing evidence that some patients with ER-positive, HER2-negative early breast cancer may be able to safely avoid chemotherapy based on genomic testing results. Researchers found that patients with a Risk of Recurrence (ROR) score of 60 or lower had excellent outcomes without chemotherapy, including premenopausal women receiving ovarian function suppression and including patients with more extensive lymph node involvement. For patients, this study is important because it supports a more personalized approach to treatment, helping identify who may benefit from chemotherapy and who may be able to avoid the added side effects and long-term impact of treatment that may not meaningfully improve outcomes.
Studies like OPTIMA reflect a broader shift happening in breast cancer care toward more personalized treatment decisions rather than a one-size-fits-all approach.
2. KEYNOTE-522 final analysis: Long-term outcomes in early-stage triple-negative breast cancer
Triple-negative breast cancer (TNBC) has historically been considered one of the more aggressive breast cancer subtypes. In recent years, immunotherapy has started changing the treatment landscape for some patients.
The KEYNOTE-522 trial helped establish pembrolizumab (Keytruda) combined with chemotherapy as a standard treatment approach for many patients with high-risk early-stage TNBC. The final analysis provides a clearer picture of the long-term benefit of adding immunotherapy to treatment for early-stage TNBC and helps patients better understand how outcomes are improving with newer treatment strategies.
At ASCO 2026, researchers presented final long-term results from the study. Long-term follow-up from the KEYNOTE-522 trial continues to strengthen evidence supporting pembrolizumab plus chemotherapy for patients with high-risk early-stage triple-negative breast cancer (TNBC). Researchers reported meaningful improvements in both event-free survival and overall survival when pembrolizumab was added before surgery alongside chemotherapy and then continued after surgery. Importantly, the benefit was seen across multiple patient groups, regardless of PD-L1 status, lymph node involvement, or disease stage. Earlier results from the trial already showed higher pathologic complete response rates, helping lead to FDA approval of this perioperative immunotherapy approach in 2021.
For patients, these updated long-term results are important because they provide encouraging evidence that adding immunotherapy may help more people with high-risk early TNBC remain cancer-free and live longer, while also helping shape future conversations around which patients may benefit from more or less intensive treatment approaches.
3. ASCENT-04: A new approach for metastatic triple-negative breast cancer
Metastatic triple-negative breast cancer remains an area of urgent unmet need, and researchers continue working to improve treatment options. The ASCENT-04 study is evaluating whether combining sacituzumab govitecan (Trodelvy) with pembrolizumab may improve outcomes for patients with PD-L1-positive metastatic TNBC. Trodelvy is part of a newer class of cancer drugs called antibody-drug conjugates, sometimes referred to as ADCs. These therapies are designed to deliver chemotherapy more directly to cancer cells.
For patients living with metastatic TNBC, ASCENT-04 is one of the studies many oncologists and advocates watched closely at ASCO 2026. This news is exciting for patients with TNBC because: “These findings strengthen the case for approval of sacituzumab govitecan as first-line treatment of patients with advanced triple-negative breast cancer who are not eligible for immunotherapy, which was evaluated in ASCENT-03, and of sacituzumab govitecan plus pembrolizumab as first-line treatment of patients whose tumors are positive for the immune checkpoint PD-L1, evaluated in ASCENT-04.”
4. SERENA-6: Using blood tests to guide treatment earlier
One of the most closely watched areas in breast cancer research right now is the use of circulating tumor DNA (ctDNA), sometimes called “liquid biopsy,” to detect molecular changes before cancer progression appears on scans. The SERENA-6 study explores whether changing to endocrine therapy (camizestrant, an oral SERD) earlier, based on emerging ESR1 mutations detected through blood testing, can improve outcomes for patients with metastatic HR-positive, HER2-negative breast cancer.
This study is important because it reflects a future many researchers believe oncology is moving toward: adapting treatment based on molecular changes happening in real time rather than waiting until the cancer visibly progresses. Patients often hear growing discussion around ctDNA testing, liquid biopsy, and ESR1 mutations, but many still have questions about what these tests mean and how they may influence care. Studies like SERENA-6 may help clarify how these tools could eventually be used in everyday clinical practice.
At ASCO 2026, the SERENA-6 study authors presented updated results that found that “camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor.” Regarding switching to the camizestrant combination following ctDNA testing, the FDA has not yet approved that usage and has requested additional analysis.
5. Neo-Healer: A closely watched late-breaking HER2-positive study
HER2-positive breast cancer continues to be one of the fastest-moving areas in cancer research, with scientists working to improve cure rates while finding more effective and potentially less toxic treatment approaches.
One of the most notable breast cancer presentations at ASCO 2026 was the Phase III Neo-Healer trial, which evaluated anbenitamab, a next-generation HER2-targeted antibody, combined with chemotherapy before surgery in patients with early-stage or locally advanced HER2-positive breast cancer. The study demonstrated that anbenitamab combined with albumin-bound docetaxel (nab-docetaxel), with or without carboplatin, significantly increased pathologic complete response (pCR) rates (complete clearing of the cancer) compared with the current standard neoadjuvant regimen of trastuzumab, pertuzumab, and docetaxel (THP), with or without carboplatin.
This marks one of the first Phase III studies to demonstrate that a single drug that targets two parts of the HER2 protein may outperform the current two drug standard of care when used before surgery.
Why does this matter? PCR means no invasive cancer can be found in the breast or lymph nodes at the time of surgery after preoperative treatment. For many patients with HER2-positive breast cancer, achieving pCR is associated with a lower risk of recurrence and improved long-term outcomes. While longer follow-up is still needed to determine whether the pCR improvement translates into better event-free or overall survival, the Neo-Healer results suggest a potentially important new treatment option may be emerging for patients with early-stage HER2-positive disease.
6. SENOMAC: Is it safe to omit lymph node removal?
Results from the Phase III SENOMAC clinical trial found that omitting an axillary lymph node dissection (ALND) was safe for breast cancer patients whose tumor had spread to 1 or 1 sentinel lymph nodes. This data is significant because it ensures patients can avoid arm-related side effects that negatively affect quality of life. Side effects from ALND can include swelling, impaired function, and pain in the arm.
Results from the SENOMAC trial add to previous studies that suggested some patients with limited lymph node involvement could avoid removal; SENOMA is important because it included a larger population inclusive of patients with larger tumors and those undergoing a mastectomy.
Why this matters for patients
Large cancer meetings like ASCO can feel overwhelming, especially when headlines start appearing without full explanation on what it could mean for you today. Not every study will change treatment immediately, and early excitement does not always translate into long-term benefit.
But these meetings can provide an important glimpse into where breast cancer care is heading.
This year’s research reflects several major themes shaping the future of breast cancer treatment:
- More personalized treatment decisions
- Better use of biomarker testing
- Expansion of immunotherapy
- Increased use of antibody-drug conjugates (ADCs)
- Earlier detection of treatment resistance through blood-based testing
For patients, staying informed can help support more meaningful conversations with your care team and a better understanding of how treatment options continue to evolve.
